The question gets asked in different ways but it's the same question. Will I lose muscle on a GLP-1? Will I be skinny-fat? Will I be weaker at 50 because I took a weight-loss medication at 45? The short answer is: a portion of the weight you lose on a GLP-1 will be lean tissue, but the size of that portion is largely under your control. Two interventions, both well-studied, do most of the work.

This is what the 2025 evidence actually shows, what the current consensus guidelines recommend, and how to operationalize them without making weight loss harder than it needs to be.

What's actually being lost

"Lean mass" in body composition studies is a slightly imprecise term. It captures skeletal muscle, but also water, organs, connective tissue, and skin. When patients lose 50 pounds, some fraction of that is muscle, some is water (skin retracts and intracellular water drops with smaller cells), and a small portion is reduction in the size of metabolically active organs like the liver. Not all "lean mass" loss is muscle loss.

That said, real muscle loss does happen. Two recent systematic reviews and meta-analyses converged on roughly 20 to 30 percent of total weight loss on a GLP-1 being lean soft tissue. A 2025 case series in SAGE Open Medical Case Reports reported a range of 26 to 40 percent across three patients tracked closely during semaglutide or tirzepatide therapy. The SURMOUNT-1 body composition substudy published in Diabetes, Obesity and Metabolism in 2025 documented similar proportions among tirzepatide patients.

This is broadly comparable to diet-induced weight loss, where the lean fraction is typically estimated at 25 to 35 percent. A March 2026 Cell Reports Medicine paper concluded that GLP-1 weight loss does not produce a disproportionate loss of muscle relative to other methods. The concern is real but it's not unique to GLP-1s; it's a feature of any negative energy balance.

Why the concern is amplified in older adults

Adults lose roughly 8 percent of their lean mass per decade after age 40 even without any intentional weight loss. Layered on top of that baseline sarcopenia, an additional 20 to 30 percent lean fraction during weight loss compounds quickly. A 60-year-old who loses 60 pounds without intervention may end up with meaningful functional deficits, including grip strength, balance, and recovery from minor illness. This is not theoretical; it's the population where the lean-mass question matters most.

For a 35-year-old in a higher BMI category losing weight, the calculus is different. The same proportional lean loss leaves more functional reserve, and the cardiovascular and metabolic benefits of weight loss generally outweigh the muscle cost. Both populations benefit from protein and resistance training, but the older population benefits more on the margin.

Protein: the consensus floor

An international working group of fifteen clinicians and nutritionists conducted a modified Delphi process from May to September 2024 and published consensus guidance for nutritional support during GLP-1 therapy. The protein recommendation: at least 1.2 grams per kilogram of body weight per day, distributed evenly across meals.

For a 200-pound (91 kg) patient, that floor is roughly 109 grams of protein per day. For a 250-pound (113 kg) patient, it's 136 grams. The 2025 joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society endorsed the same threshold.

Many clinicians and registered dietitians working with GLP-1 patients recommend pushing higher, typically 1.6 grams per kilogram or more. The case series cited above reported intakes of 0.7 to 1.7 grams per kilogram of body mass and 1.6 to 2.3 grams per kilogram of fat-free mass among patients who successfully preserved lean tissue. Above approximately 1.6 grams per kilogram, the marginal benefit drops off; below 1.2 grams per kilogram, lean mass loss accelerates regardless of training.

The practical challenge

The hard part is that GLP-1s suppress appetite. Reaching 130 grams of protein when you're not hungry is genuinely difficult. A few patterns that work:

Resistance training: the bigger lever

If protein is the substrate, resistance training is the signal. Muscle is built and preserved by mechanical loading; protein alone, without the stimulus, doesn't do the job. The consensus prescription is consistent across the 2025 guidelines: structured resistance training at least three times per week.

"Resistance training" in this context means progressively loading the major muscle groups against external resistance. Bodyweight exercises count at the beginning; most patients should progress to weighted training (dumbbells, machines, barbells) within a few months. The specific program matters less than the principles:

The minimum effective dose

For patients who haven't strength-trained before, the floor is two sessions per week of 30 to 45 minutes covering full-body resistance work. Three sessions per week is better. Four is better still, with diminishing returns above that for most populations. The 150 minutes of weekly aerobic exercise recommended in parallel by the major guidelines is for cardiovascular health, not lean mass preservation; the aerobic component does not substitute for resistance training.

The data on combination

The 2025 case series cited above tracked three patients who prioritized lean mass preservation strategies during GLP-1 therapy. All three engaged in intentional exercise four to seven days per week, with resistance training three to five days per week, and protein intakes of 0.7 to 1.7 grams per kilogram of body mass. All three preserved lean mass within an acceptable range and lost predominantly fat. The sample size is small but the pattern is consistent with the broader literature.

The phase 2 EMBRAZE trial (Scholar Rock, results reported June 2025) tested apitegromab, a myostatin pathway inhibitor, added to tirzepatide. The trial demonstrated statistically significant preservation of lean mass during tirzepatide-induced weight loss compared to tirzepatide alone. This is preliminary and the drug is not yet available, but it suggests a future where pharmacologic adjuncts may further support lean mass preservation. For now, protein and resistance training are the proven tools.

Common mistakes

For older adults specifically

The data on sarcopenia and weight loss in adults over 65 is the strongest argument for taking the lean-mass question seriously. Several practical adjustments:

The Bottom Line

Roughly a quarter of GLP-1 weight loss is lean tissue, which is consistent with other methods of weight loss and not unique to the medication. The fraction is meaningfully smaller for patients who eat at least 1.2 grams of protein per kilogram of body weight per day and engage in structured resistance training three or more times per week. Both interventions are well-studied, freely available, and have been endorsed by every major obesity medicine guideline published in 2025. The medications do their job; the responsibility to preserve muscle is partly behavioral, and it pays off.

This is a question to discuss with your provider, especially if you're over 50, were sedentary before starting therapy, or have a history of low muscle mass. The plan is straightforward; the execution is the work.